ALNY•benzinga•
Alnylam Announced APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy Met Primary Endpoint, First Secondary Endpoint
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 8, 2022 by benzinga